Clinical trials
Observational Eye Diseases trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 3 |
| 2004 | 2 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 6 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Active, not recruiting | 6 |
| Recruiting | 6 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Eye Institute (NEI) | 13 |
| Nanoscope Therapeutics Inc. | 3 |
| Adverum Biotechnologies, Inc. | 2 |
| University of Colorado, Denver | 2 |
| Vanderbilt University Medical Center | 2 |
| American Academy of Ophthalmology | 1 |
| Anova Enterprises, Inc | 1 |
| Complement Therapeutics | 1 |
| Duke University | 1 |
| Editas Medicine, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eye Diseases | 40 |
| Retinal Diseases | 8 |
| Retinal Degeneration | 6 |
| Eye Diseases, Hereditary | 5 |
| Glaucoma | 4 |
| Macular Degeneration | 4 |
| Blindness | 3 |
| Retinal Dystrophies | 3 |
| Retinitis Pigmentosa | 3 |
| Cataract | 2 |
Trials
Showing 1 to 25 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.